Optimal Choice of Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer: Clinical Insights

The neoadjuvant setting provides immense opportunities for translational research and drug development. The acceptance of pathological complete response (pCR) as a surrogate endpoint for clinical benefit has led to the widespread use of neoadjuvant treatment. Optimal neoadjuvant therapies are determ...

Descripción completa

Detalles Bibliográficos
Autores principales: Lucas, Mairi W, Kelly, Catherine M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393016/
https://www.ncbi.nlm.nih.gov/pubmed/35999966
http://dx.doi.org/10.2147/CMAR.S341466

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393016/
https://www.ncbi.nlm.nih.gov/pubmed/35999966
http://dx.doi.org/10.2147/CMAR.S341466

Ejemplares similares